Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKinsey
Fuji
Harvard Business School
Cipla
Citi
Federal Trade Commission
Dow
Mallinckrodt

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CRESTOR

« Back to Dashboard

Clinical Trials for Crestor

Trial ID Title Status Sponsor Phase Summary
NCT00079638 Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL Completed Kos Pharmaceuticals Phase 4 The purpose of this study is to evaluate the effectiveness of first-line treatment using Niaspan (an extended release version of niacin) and statins versus other drugs that lower lipid levels, in subjects with elevated fat levels in their blood (dyslipidemia). Statins are a class of medication that is often prescribed to patients who need to lower their cholesterol levels.
NCT00115830 Rho Kinase in Patients With Atherosclerosis Completed Brigham and Women's Hospital Phase 3 The purpose of the study is to investigate the effects of atorvastatin (Lipitor) and rosuvastatin (Crestor), United States Food and Drug Administration (FDA) approved drugs commonly prescribed by doctors to lower cholesterol, on certain functions of platelets (cells that cause blood clots), white blood cells (cells that are responsible for inflammation), and blood flow regulation by arteries. This is important because we are looking at ways to more effectively prevent atherosclerosis (plaque buildup in blood vessels) and heart disease. Many studies have demonstrated that these drugs are effective at reducing inflammation and stabilizing plaques. We are interested in better understanding the effects of these medicines on inflammation (pain and swelling) and the mechanism by which they act. Hypothesis: Atorvastatin (40mg) will reduce inflammatory markers and activity more than Rosuvastatin (10mg) in spite of equal LDL-C reduction.
NCT00184951 Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients Completed Abbott Phase 2 open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.
NCT00184951 Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients Completed AstraZeneca Phase 2 open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.
NCT00184951 Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients Completed Radboud University Phase 2 open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Crestor

Condition Name

Condition Name for Crestor
Intervention Trials
Hypercholesterolemia 26
Atherosclerosis 17
Hyperlipidemia 10
Healthy 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Crestor
Intervention Trials
Hypercholesterolemia 33
Atherosclerosis 21
Coronary Artery Disease 20
Myocardial Ischemia 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Crestor

Trials by Country

Trials by Country for Crestor
Location Trials
United States 378
Canada 72
Italy 36
Japan 34
Mexico 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Crestor
Location Trials
California 17
Texas 15
Ohio 14
New York 13
Florida 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Crestor

Clinical Trial Phase

Clinical Trial Phase for Crestor
Clinical Trial Phase Trials
Phase 4 38
Phase 3 39
Phase 2/Phase 3 2
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Crestor
Clinical Trial Phase Trials
Completed 95
Recruiting 14
Terminated 13
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Crestor

Sponsor Name

Sponsor Name for Crestor
Sponsor Trials
AstraZeneca 45
Odense University Hospital 4
Merck Sharp & Dohme Corp. 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Crestor
Sponsor Trials
Other 103
Industry 91
NIH 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Merck
Healthtrust
QuintilesIMS
Moodys
Boehringer Ingelheim
Federal Trade Commission
Mallinckrodt
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.